Gilead Sciences, Inc.
NEWS
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
Researchers with the Georgia Institute of Technology recently published work that describes several new approaches to improving CAR-T, particularly for solid tumors.
The Phase II study showed that the asset achieved antiviral activity in healthy patients and set the stage for AT-527’s potential as a preventative treatment for COVID following exposure to the virus.
JOBS
IN THE PRESS